
    
      A phase 2, randomized, double-blind, placebo-controlled clinical study of Nexvax2, in adults
      subjects with confirmed CeD who have been following a gluten free diet for at least 12
      consecutive months prior to screening. This study will evaluate efficacy of Nexvax2
      administered subcutaneously. The study plan consists of 3 periods: a screening period of 6
      weeks, an approximately 16 week treatment period, and a 4 week post-treatment observational
      follow-up.
    
  